Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma
about
Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugsMetabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentialityEfficacy and safety of eribulin mesylate in advanced soft tissue sarcomasPhase I study of pazopanib plus TH-302 in advanced solid tumors.Hypoxia-activated prodrug TH-302 decreased survival rate of canine lymphoma cells under hypoxic conditionEnhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.High Resolution Ultrasound and Photoacoustic Imaging of Orthotopic Lung Cancer in Mice: New Perspectives for Onco-Pharmacology.Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models.A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patientsHypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas.[Soft tissue sarcoma: a report of 33 cases]Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models.Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models.In Vivo Bioorthogonal Chemistry Enables Local Hydrogel and Systemic Pro-Drug To Treat Soft Tissue SarcomaComparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models.Phase III Soft Tissue Sarcoma Trials: Success or Failure?Current and advancing systemic treatment options for soft tissue sarcomas.Histology-Driven Therapy: The Importance of Diagnostic Accuracy in Guiding Systemic Therapy of Soft Tissue Tumors.Virus-directed enzyme prodrug therapy and the assessment of the cytotoxic impact of some benzimidazole derivatives.Emerging targets for radioprotection and radiosensitization in radiotherapy.CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximabEfficient Protocol for the Identification of Hypoxic Cell Radiosensitisers.Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapyBO-1055, a novel DNA cross-linking agent with remarkable low myelotoxicity shows potent activity in sarcoma models.Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide.Development and characterization of a human three-dimensional chondrosarcoma culture for in vitro drug testing.Hypoxia Imaging With PET Correlates With Antitumor Activity of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) in Rodent Glioma Models.Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma.Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.Hypoxia Marker GLUT-1 (Glucose Transporter 1) is an Independent Prognostic Factor for Survival in Bladder Cancer Patients Treated with Radical Cystectomy.Engineered Breast Cancer Cell Spheroids Reproduce Biologic Properties of Solid Tumors.Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer.Radiotherapy Synergizes with the Hypoxia-Activated Prodrug Evofosfamide: In Vitro and In Vivo Studies.Theranostic Liposomes with Hypoxia-Activated Prodrug to Effectively Destruct Hypoxic Tumors Post-Photodynamic Therapy.Established Models and New Paradigms for Hypoxia-Driven Cancer-Associated Bone Disease.Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models.
P2860
Q26774750-BAE6B333-A6B9-4AD8-8DA5-8C9CA43B3F77Q27025007-C554D9AD-AA95-4C92-89BB-ADB0528C924FQ28078116-F4A7F4DB-B1BD-4099-9768-98E577067C25Q33439635-91471F36-5F3D-4D23-81D1-FFDF799B121DQ33657282-2852DA4C-99C9-4D99-94F0-89C50ACAAFB0Q35637224-A78C5483-FC6D-4075-A435-0B7A129E440DQ35987173-764CF4E8-801C-40CC-B177-1DB76AC41380Q35993104-2E4E4355-FFE5-4AA9-96C6-4DD674DA151AQ36106434-8A28834A-3F5D-4E85-9C4D-26A01DA13F1FQ36286658-D71E81AD-D3EF-4022-B370-5ECB205D7D41Q36680253-65279D30-D6DB-48AB-AA34-C7E767E3FBCFQ36706902-2AE6DD91-A015-4D60-8F53-3C5C1C4382A6Q36759062-B974B85C-6E41-465E-AA8F-F3EA43348951Q37137443-CFD8BCB6-4758-4648-BB0C-CAFF067E955DQ37283967-937220AF-E4D1-4EE2-ADD0-597BC13FE51CQ37716872-498A93D8-B4C8-4F70-B6D6-23552D24AD50Q38563242-11C3A68D-DCB1-4DA2-B3C1-1B876751EF49Q38591828-75FBA9F8-28B8-471C-B392-BB37B87EA0C0Q38696221-2C544794-6A07-46EA-B4E9-507EB8429374Q38869603-6B147512-E7EE-449A-80F0-4BA416FB9A44Q38885166-C7FC26F4-10AD-4775-A88F-6AD02AE021E8Q39668588-ADC35A03-26EA-4BC0-9120-589B1268DB21Q39984948-2760E253-A8CC-4958-B746-E50DD5E3D56FQ39985326-1B78CAAF-A500-4B10-9CC5-FB1E70B858EAQ40862337-D2683563-60E4-4C79-B2EE-DAF5CDEFECE6Q41007674-A674C932-8C49-472A-8597-1B1CAC76FCE9Q41467964-D6C2438B-F9D9-4D10-811E-2A0D71A25286Q41712371-92C80111-7E44-4D92-993D-BFFBD0B641F6Q42417074-1B7E078F-D7B1-4B6F-9143-BD444B49C6B5Q42488078-9747279B-A928-4CB0-AFCA-B78D57153DDEQ42835560-378093DD-9A36-4682-9CC0-51F71D47C66BQ46013875-0570EFE9-AE08-48AC-8F56-E01CDB05ABB3Q46018609-55E03B8A-B194-41E1-A977-7C291638E4B1Q48114384-A732011E-D650-4749-925E-A38178940D19Q48371418-E506E3E9-4831-4060-97D7-4921BFB026BEQ55555244-323B058E-1642-492B-997E-28DDE060B69B
P2860
Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Phase II study of the safety a ...... h advanced soft tissue sarcoma
@ast
Phase II study of the safety a ...... h advanced soft tissue sarcoma
@en
type
label
Phase II study of the safety a ...... h advanced soft tissue sarcoma
@ast
Phase II study of the safety a ...... h advanced soft tissue sarcoma
@en
prefLabel
Phase II study of the safety a ...... h advanced soft tissue sarcoma
@ast
Phase II study of the safety a ...... h advanced soft tissue sarcoma
@en
P2093
P2860
P356
P1476
Phase II study of the safety a ...... h advanced soft tissue sarcoma
@en
P2093
Andrew E Hendifar
Brian A Van Tine
Douglas R Adkins
James E Butrynski
Kristen N Ganjoo
Lee D Cranmer
Sant P Chawla
Scott H Okuno
Stew Kroll
P2860
P304
P356
10.1200/JCO.2013.54.3660
P407
P577
2014-09-02T00:00:00Z